Company Filing History:
Years Active: 2025
Title: Philippe Ochsenbein: Innovator in Cardiac Treatment
Introduction
Philippe Ochsenbein is a notable inventor based in Montpellier, France. He has made significant contributions to the field of cardiac treatment through his innovative research and development.
Latest Patents
Ochsenbein holds a patent for novel polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide. This invention is particularly useful for treating various cardiac disorders, including systolic dysfunction, dilated cardiomyopathy (DCM), and heart failure with preserved ejection fraction (HFrEF). The patent details the synthesis and characterization of these polymorphs, as well as methods for treating heart disease.
Career Highlights
Philippe Ochsenbein is associated with Myokardia, Inc., a company focused on developing innovative therapies for heart disease. His work has been instrumental in advancing treatment options for patients suffering from cardiac conditions.
Collaborations
Ochsenbein has collaborated with notable colleagues, including Min Zhong and Olivier Monnier, to further enhance the research and development of cardiac treatments.
Conclusion
Philippe Ochsenbein's contributions to cardiac treatment through his innovative patent and collaboration with esteemed colleagues highlight his importance in the field of medical research. His work continues to pave the way for advancements in therapies for heart disease.